R. Johansson et T. Werner, Syntheses of two [C-14]-labeled disodium 4-[(N-tert-butylimino)methyl]benzene-1,3-disulfonate N-oxides, J LABEL C R, 43(13), 2000, pp. 1265-1273
NXY-059 (5) is a new chemical entity developed as a putative agent for the
treatment of acute and chronic neurological degenerative disorders. It is c
urrently undergoing clinical evaluation for the treatment of stroke. In ord
er to study the metabolic transformation and organ distribution of the comp
ound, radiolabeled NXY-059 was needed. In this paper; we describe the synth
esis of two differently carbon-14 labeled disodium 4-[(N-tert-butylimino)me
thyl]benzene-1,3-disulfonate N-oxides.